Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: exploratory study using primary and paired metastatic lesions

Table 1 Comparison of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, Ki-67, and enhancer of zeste homolog 2 biomarkers between primary lesions and metastatic lesions in breast cancer patients (n = 96)

Biomarker	Primary lesions	Metastatic lesions	P-value
ER status, n (%)
positive	51 (53.1)	41 (42.7)	0.149
negative	45 (46.9)	55 (57.3)
PR status, n (%)
positive	47 (49.0)	39 (40.6)	0.246
negative	49 (51.0)	57 (59.4)
HER2 status, n (%)
positive	16 (16.7)	14 (14.6)	0.691
negative	80 (83.3)	82 (85.4)
Ki-67 expression, n (%)
high	55 (57.3)	72 (75.0)	0.010^*
low	41 (42.7)	24 (25.0)
EZH2 expression, n (%)
high	54 (56.3)	79 (82.3)	<0.0001^*
low	42 (43.7)	17 (17.7)
Molecular subtype, n (%)
luminal A^a	31 (32.3)	19 (19.8)	0.304
luminal B^b	22 (22.9)	29 (30.2)
luminal HER2^c	5 (5.2)	5 (5.2)
HER2-type^d	11 (11.5)	9 (9.4)
TNBC^e	27 (28.1)	34 (35.4)

Abbreviations: ER estrogen receptor, EZH2 enhancer of zeste homolog 2, HER2 human epidermal growth factor receptor 2, PR progesterone receptor, TNBC triple-negative breast cancer
^aLuminal A = ER and/or PR+, HER2−, and low Ki-67 expression
^bLuminal B = ER and/or PR+, HER2−, and high Ki-67 expression
^cLuminal HER2 = ER and/or PR+, HER2+
^dHER2-type = ER and PR−, HER2+
^eTNBC = ER and PR−, HER2−
^*Indicates values that are statistically significant (P < 0.05)

ISSN: 1471-2407